在阿尔茨海默病,亨廷顿病和帕金森病中使用BEST的比较平衡
Lauren E Tueth1, Ryan P Duncan1,2, Beth E Crowner1,2
1Washington University in St. Louis School of Medicine, Program in Physical Therapy, St. Louis, MO 63108, USA.
Neurodegenerative disease management
|August 19, 2024
概括
患有帕金森病的人比患有阿尔茨海默病或亨廷顿病的人更容易出现平衡障碍. 阿尔茨海默氏症和亨廷顿病患者在早期表现出类似的平衡缺陷,这表明病理重叠.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 运动障碍 运动障碍
背景情况:
- 失衡是神经退行性疾病的常见症状,如阿尔茨海默病 (AD),亨廷顿病 (HD) 和帕金森病 (PD).
- 在这些疾病中比较平衡赤字可能会提供有关疾病进展和神经疾病管理策略的见解.
研究的目的:
- 为了比较早期被诊断患有AD,HD和PD的个体的平衡障碍.
- 调查这些神经退行性疾病中平衡赤字的潜在差异或相似之处.
主要方法:
- 使用平衡评估系统测试 (BESTest) 来评估平衡.
- 在三个不同的群体中比较BEST的得分:患有早期AD,HD和PD的个体.
主要成果:
- 与阿尔茨海默病 (AD) 患者相比,患有帕金森病 (PD) 的个人表现出明显更高的BESTest得分 (95% CI [4.30,21.37],p < 0.01).
- 患PD患者的BESTest评分也明显高于亨廷顿病 (HD) 患者 (95% CI [6.53,24.18],p < 0.001).
- 在阿尔茨海默病和HD患者之间,总体BESTest得分或分节得分没有显著差异.
结论:
- 帕金森病与阿尔茨海默氏症和亨廷顿病相比,在早期阶段与更明显的平衡障碍有关.
- 在早期的AD和HD中观察到的类似的平衡赤字表明潜在的重叠病理机制有助于在这些条件下影响平衡.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Parkinson's Disease: Overview
501
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
501
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Dementia
108
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
108
Parkinson's Disease: Treatment
240
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
240


